United States - English - NLM (National Library of Medicine)

remedyrepack inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg - abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. abacavir tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions ( 5.1)]. - with prior hypersensitivity reaction to abacavir [see warnings and precautions ( 5.1)].  - with moderate or severe hepatic impairment [see use in specific populations ( 8.6)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data). the apr uses the ma

United States - English - NLM (National Library of Medicine)

apotex corp - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg - abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. abacavir tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)]. - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)].  - with moderate or severe hepatic impairment [see use in specific populations (8.6)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data). the apr uses the macdp a

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 20 mg in 1 ml - abacavir oral solution in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection. abacavir oral solution is contraindicated in patients: • who have the hla-b*5701 allele [see warnings and precautions (5.1)]. • with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)]. • with moderate or severe hepatic impairment [see use in specific populations (8.6)]. teratogenic effects: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr)at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference pop

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg - abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. abacavir tablet is contraindicated in patients: • who have the hla-b*5701 allele [see warnings and precautions (5.1)]. • with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)]. • with moderate or severe hepatic impairment [see use in specific populations (8.6)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for major birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data). the apr

United States - English - NLM (National Library of Medicine)

mikart, llc - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 50 mg in 5 ml - isoniazid oral solution is recommended for all forms of tuberculosis in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. isoniazid oral solution is recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parentheses): additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: children who are less than 4 years old are candidates for isoniazid preventive therapy if they have greater than 10 mm induration from a ppd mantoux tuberculin

United States - English - NLM (National Library of Medicine)

mikart, llc - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 100 mg - isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculosis with isoniazid, or any other medication is inadequate therapy. isoniazid is recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parentheses): additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: children who are less than 4 years old are candidates for isoniazid preventive therapy if they have > 10 mm induration from a ppd mantoux tuberculin skin test. finally, persons under the

United States - English - NLM (National Library of Medicine)

bausch health us, llc - edetate calcium disodium (unii: 25ih6r4sgf) (edetic acid - unii:9g34hu7rv0) - edetate calcium disodium 200 mg in 1 ml - edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. edetate calcium disodium should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.

United States - English - NLM (National Library of Medicine)

appco pharma llc - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg

United States - English - NLM (National Library of Medicine)

acetris health, llc - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 100 mg - zidovudine capsules , a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine capsules are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included 3 components: - antepartum therapy of hiv-1-infected mothers - intrapartum therapy of hiv-1-infected mothers - post-partum therapy of hiv-1-exposed neonate points to consider prior to initiating zidovudine capsules in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine capsules for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine capsules for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratoge

United States - English - NLM (National Library of Medicine)

akrimax pharmaceuticals, llc - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 5 mg